Neutropenic Fever
8
1
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Antibiotic Stewardship in Suspected Neutropenic Fever (ASTERIC Trial)
Pharmacokinetics and Safety of AmBisome and DKF-5122
Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection
Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever